| Non-Hodgkin Lymphoma (NHL) |
0 |
0.9 |
| Diffuse Large Cell Lymphoma |
0 |
1 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.51 |
| Biologic Therapy |
0 |
0.48 |
| Proteasome Inhibitor |
0 |
0.38 |
| Genomic Medicine |
0 |
0.35 |
| Toxicology |
0 |
0.35 |
| Lymphoma |
0 |
0.17 |
| B-Cell Lymphoma |
0 |
0.99 |
| Follicular Lymphoma |
0 |
0.14 |
| Chronic Lymphocytic Leukemia |
0 |
0.1 |
| Antineoplastic Drug |
0 |
0.09 |
| Monoclonal Antibody |
0 |
0.09 |
| Pathogenesis |
0 |
0.09 |
| Genetics |
0 |
0.06 |
| Tyrosine Kinase |
0 |
0.06 |
| Patient Safety |
0 |
0.04 |
| Addiction |
0 |
0.03 |
| Adverse Effects |
0 |
0.03 |
| Chemotherapy |
0 |
0.03 |
| Clinical Research |
0 |
0.03 |
| Grant |
0 |
0.03 |
| Hospital |
0 |
0.03 |
| Immunomodulator |
0 |
0.03 |
| Intravenous |
0 |
0.03 |
| Leukemia |
0 |
0.03 |
| Receptors |
0 |
0.03 |
| Refractory |
0 |
0.03 |
| Spleen |
0 |
0.03 |